Status:
NOT_YET_RECRUITING
Total Neoadjuvant 6 Cycles of Chemotherapy Versus 3 Cycles in Partial Responder Patients Diagnosed With Epithelial Ovarian Cancer
Lead Sponsor:
Assiut University
Conditions:
Stage III and IV Ovarian Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE3
Brief Summary
neoadjuvant chemotherapy in stage III and IV ovarian cancer is given in 3-4 cycles with patients who R0 surgical resection is less likely to occur, in this study will assess total neoadjuvant chemothe...
Eligibility Criteria
Inclusion
- \> 18 years of age
- Recently diagnosed with stage III and IV OC
- Patients eligible for Platinum-based CTH
- Patients have PR or SD after 3-4 cycles of NACT
Exclusion
- Relapsed ovarian cancer
- patients ineligible for Platinum-based CTH
- Patient not candidate for IDS
- stage I, II OC
- Patients progressed after 3 cycles
- 7-Patients do not tolerate CTH
Key Trial Info
Start Date :
June 30 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 30 2028
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06980545
Start Date
June 30 2025
End Date
May 30 2028
Last Update
May 20 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.